Author

Christine Flefleh

Observed names: C Flefleh, C. Flefleh

Institution: Bristol-Myers Squibb (United States)

Observed institutions: The University of Texas MD Anderson Cancer Center, Bristol-Myers Squibb (United States)

OpenAlex ID: A5055799863

Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical Exposure

2006 · Feng R. Luo, Zheng Yang, et al. · Clinical Cancer Research · 150

Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft

2005 · F. R. Luo, Z. Yang, et al. · Cancer Chemotherapy and Pharmacology · 84

Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels

2006 · Robert Wild, Krista Fager, et al. · Molecular Cancer Therapeutics · 62

Chronotherapy and chronotoxicity of the cyclooxygenase-2 inhibitor, celecoxib, in athymic mice bearing human breast cancer xenografts.

2001 · R D Blumenthal, C Waskewich, et al. · PubMed · 50

BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad-spectrum antitumor activities in vitro and in vivo

2005 · Francis Y. Lee, Louis J. Lombardo, et al. · Cancer Research · 40

Preclinical efficacy evaluation of ixabepilone (BMS-247550) in combination with cetuximab or capecitabine in human colon and lung carcinoma xenografts

2006 · F. Y. Lee, A. Camuso, et al. · Journal of Clinical Oncology · 30

Prediction of Active Drug Plasma Concentrations Achieved in Cancer Patients by Pharmacodynamic Biomarkers Identified from the Geo Human Colon Carcinoma Xenograft Model

2005 · Feng R. Luo, Zheng Yang, et al. · Clinical Cancer Research · 25

Dasatinib (BMS-354825) Overcomes Multiple Mechanisms of Imatinib Resistance in Chronic Myeloid Leukemia (CML).

2005 · Francis Y. Lee, Mei-Li Wen, et al. · Blood · 18

BMS-354825, a Dual SRC/ABL Kinase Inhibitor, Displays Potent Anti-Tumor Activity in a Model of Intracranial CML Growth.

2004 · Robert Wild, Stephen Castaneda, et al. · Blood · 11

Quiescent Chronic Myelogenous Leukemia (CML) Cells Are Resistant to BCR-ABL Inhibitors but Preferentially Sensitive to BMS-214662, a Farnesyltransferase Inhibitor (FTI) with Unique Quiescent-Cell Selective Cytotoxicity.

2005 · Francis Y. Lee, Mei-Li Wen, et al. · Blood · 5

Pharmacodynamic analysis of target inhibition and tumor endothelial cell death in biopsies obtained from patients treated with the VEGF receptor antagonists SU5416 or SU6668

2004 · Francis Y. Lee, Louis J. Lombardo, et al. · Cancer Research · 5

Pharmacokinetics- and Pharmacodynamics-Guided Optimization of the Dose and Treatment Schedule for the Dual SRC/ABL Inhibitor BMS-354825.

2004 · Feng Roger Luo, Zheng Yang, et al. · Blood · 3

Works count: 12

Citation count: 483

H-index: 9

I10-index: 9